Sitemap > Breaking Research > Cardiovascular Disorders
Displaying 551 - 600 of 4862 results
- HIV-based vectors and angiogenesis following rabbit hindlimb ischemia.
- Synthesis and structure-activity relationships of 6-{4-[(3-fluorobenzyl)oxy]phenoxy}nicotinamide derivatives as a novel class of NCX inhibitors: a QSAR study.
- Synthesis and structure-activity relationships of benzyloxyphenyl derivatives as a novel class of NCX inhibitors: effects on heart failure.
- In vivo adenosine receptor preconditioning reduces myocardial infarct size via subcellular ERK signaling.
- Extending the cardioprotective window using a novel delta-opioid agonist fentanyl isothiocyanate via the PI3-kinase pathway.
- The vascular effects of doxazosin in hypertension complicated by metabolic syndrome.
- RNA polymerase IV directs silencing of endogenous DNA.
- Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer.
- Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
- Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent.
- Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells.
- Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC.
- Cimetidine inhibits angiogenesis and suppresses tumor growth.
- BMS-191095, a cardioselective mitochondrial K(ATP) opener, inhibits human platelet aggregation by opening mitochondrial K(ATP) channels.
- Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas.
- Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.
- Discovery of a novel class of reversible non-peptide caspase inhibitors via a structure-based approach.
- Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice.
- Endogenous p53 protects vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout mice.
- Adenovirus-mediated gene transfer of heparin-binding epidermal growth factor-like growth factor enhances neurogenesis and angiogenesis after focal cerebral ischemia in rats.
- Anti-angiogenic properties of plaunotol.
- Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.
- First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.
- Thrombophilic risk factors in patients with severe carotid atherosclerosis.
- In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
- Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane.
- Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.
- Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study.
- Imaging of tumor angiogenesis in rat brains in vivo by photoacoustic tomography.
- Insulin sensitivity and endothelial function in hypertension: a comparison of temocapril and candesartan.
- Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals.
- A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
- Engineering of vault nanocapsules with enzymatic and fluorescent properties.
- Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms.
- Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
- Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction.
- Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).
- Ischemic preconditioning as induction of ischemic tolerance after transient ischemic attacks in human brain: its clinical relevance.
- Discovery of novel non-peptidic ketopiperazine-based renin inhibitors.
- Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
- AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice.
- Comparison of the safety and efficacy of emboli prevention devices versus platelet glycoprotein IIb/IIIa inhibition during carotid stenting.
- Nesiritide for secondary pulmonary hypertension in patients with end-stage heart failure.
- Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
- Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial.
- High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension.
- A study of statin use in the prevention of cognitive impairment of vascular origin in the UK.
- Connective tissue growth factor is overexpressed in complicated atherosclerotic plaques and induces mononuclear cell chemotaxis in vitro.
- Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability.
- Adenoviral gene transfer of FGF-5 to hibernating myocardium improves function and stimulates myocytes to hypertrophy and reenter the cell cycle.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 Next >